DOCSLIB.ORG

NEWSLETTER INDONESIA RESEARCH PARTNERSHIP on INFECTIOUS DISEASE July 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NEWSLETTER INDONESIA RESEARCH PARTNERSHIP on INFECTIOUS DISEASE July 2018 Issue #58 INA-RESPOND NEWSLETTER INDONESIA RESEARCH PARTNERSHIP ON INFECTIOUS DISEASE July 2018 Requesting Study Data INDONESIA FOR PUBLICATION DELEGATION VISIT TO PURPOSES US-NIH The Art of Using Wikipedia for Research Teixobactin and Odilorhabdins: A New Hope in Antimicrobial Resistance Era NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT MINISTRY OF HEALTH REPUBLICINA OF-RESPOND INDONESIA Newsletter. All rights reserved. 1 2018 July 2018 Edition INA-RESPONDThe Steering Hermitage Committee Hotel, Meeting A Tribute8-9 August Portfolio 2018 Hotel, The HermitageJakarta Hotel, A Tribute Portfolio Hotel, Photo:Jakarta Dedy Hidayat 2 Issue #58 INA-RESPOND newsletter content July 2018 Edition | issue #58 EDITOR-IN-CHIEF M. Karyana EXECUTIVE EDITOR 4 Study Updates Herman Kosasih CREATIVE DIRECTOR Dedy Hidayat 6 Reports ART DIRECTOR Antonius Pradana SENIOR WRITERS 9 Science & Research Aly Diana, M. Helmi Aziz, Mila Erastuti REVIEWERS & CONTRIBUTING 14 Comic Corner MASTHEAD WRITERS Anandika Pawitri, Dona Arlinda, Dedy Hidayat, Herman Kosasih, Lois E. Bang, Maria Intan, M. Ikhsan FEATURES Jufri, Neneng Aini, Nurhayati THANK YOU INA-RESPOND Network & Partners INA-RESPOND Secretariat Badan Penelitian dan Pengembangan Kesehatan RI, Gedung 4, Lantai 5. Jl. Percetakan Negara no.29, Jakarta 10560 www.ina-respond.net INA-RESPOND Newsletter. All rights reserved. 3 July 2018 Edition NewsletterINA-RESPOND TRIPOD & INA-PROACTIVE Study Updates By: ANANDIKA PAWITRI, CALEB L. HALIM, LOIS E. BANG, M. IKHSAN JUFRI, VENTY MULIANA SARI Screening INA102 and Enrolment y 16 July 2018, sites had enrolled B 354 subjects. Sites enrolled 72.6% of screened patients (487 screened patients). Total subjects enrolled based on our enrolment target is 57% (354 from 660). Enrolment progress until 16 July 2018 can be seen in the graphic on the right. Reasons for “Other” Reason There are many reasons why potential subjects cannot be in our study. If the reasons are not included in the inclusion or exclusion criteria, we will put them in ‘other’ category. On the right is the information: Sites updates Site 510 (Hasan Sadikin Hospital, Bandung) will join us in TRIPOD study in the near future. The complete site team members will be announced soon. Site 600 has joined the study. Dr Hendra Gani Meanwhile, the Secretariat is preparing for the Site Harahap as a new Research Assistant will accompany Preparation Visit. dr Dashari in the study. 4 Issue #58 IV study has been active for six for final document of permission to be signed by the months, and up to 23 July a Hospital Director. Unfortunately, we have not INA104 total of 326 subjects has been received news from site 670 regarding the contract H enrolled (311 adult and 15 with INA-RESPOND. pediatrics subjects). Sites enrolled 70% of screened The aim of INA-RESPOND is to build quality research patients (468 screened patients). Enrolment failure network in Indonesia. That also means we have to reason is mostly because the patients were spread our wings from far west to the far east of represented by their family members when they came Indonesia. Now with the HIV study, we have to the clinic (not by themselves). Two new sites, collaborated with hospitals in Papua island located in STUDY UPDATES Ansari Saleh Hospital and Persahabatan Hospital, the far east of Indonesia. Next month we will conduct each enrolled one subject last week. Site Assessment Visit to three cities in Papua; Sorong, No new additional site signed contract this month. Jayapura, and Merauke. As for the far west part of Currently, our legal officer is working on extending Indonesia, we have send Collaboration letter with the contract with all 12 sites since all contracts Zainoel Abidin Hospital, Aceh and are still waiting for expired on 15 June. their favourable reply. This week (23 – 26 July) we are conducting Site Per 23 July, INA-PROACTIVE is implementing protocol Preparation Visit to Site 660 (Wahab Sjahranie Version 2.0. All sites that already have PIMA Analyzer Hospital) in Samarinda. Site 640 (St. Carolus Hospital) may proceed according to the latest protocol version. and Site 650 (Budi Kemuliaan Batam Hospital) are However, sites that do not have the PIMA Analyzer working on the final preparations for site activation. will have to hold the testing until Secretariat send Hopefully, within two weeks these two sites will join them one. Regardless, all active sites will use SDW the study. Site 580 has been granted Local Ethical and CRF Version 2.0. Committee approval for HIV Study and is now waiting Enrolled Enrolled Site Activation Site Activation Subjects Subjects Site 610 09 Jan Site 570 26 Apr 70 24 (Tangerang Hospital) 2018 (Soetomo Hospital) 2018 Site 630 Site 600 12 Mar 10 Jul 50 (Ansari Saleh Hospi- 1 (Adam Malik Hospital) 2018 2018 tal) Site 550 13 Mar Site 590 18 Jul 53 1 (Wahidin Hospital) 2018 (Sardjito Hospital) 2018 Site 530 3 May (Cipto Mangunkusumo 22 2018 Hospital) INA-RESPOND Newsletter. All rights reserved. 5 July 2018 Edition NewsletterINA-RESPOND INDONESIA DELEGATION VISIT TO THE US-NIH By: HERMAN KOSASIH, M. KARYANA REPORT RePORT and CFAR Collaboration culosis (TB) research. TB researchers prognosis, TB pathogenesis, TB Meeting from all countries under RePORT diagnostics, TB treatment response collaborative meeting of consortia were invited, along with and mortality, TB/HIV in pediatrics, the CFAR investigators who have and TB HIV diabetes trisection. At RePORT (Regional Pro- expressed an interest in the poten- the end of the meeting, future re- spective Observational tial of this proposed collaboration search areas of interest were shared Research in Tuberculo- A and in the portfolio of Tuberculosis and partnerships for future cross- sis) and CFAR (Center for AIDS Re- search) was conducted on 2-3 July Research. During this productive consortia collaborations to enhance 2008. The purpose of this meeting meeting, current research portfolios synergy and advance TB/HIV re- were shared, including research on was to understand the resources search were discussed. the epidemiology of TB, biomarkers and gaps in US-NIH funded Tuber- in TB prevention, diagnosis and 6 Issue #58 INA-RESPOND Newsletter. All rights reserved. 7 July 2018 Edition the team of-the-art features inside this se- from the cure laboratory. National On the third day, Dr Clifford Lane, Institute of the deputy of US-NIAID, head of Mental Clinical Center and our INA- Health RESPOND governing board mem- (NIMH). ber, accepted the delegation. Dur- On the sec- ing the one and half hour meeting, ond day, US Dr Lane explained the structure of -NIAID pre- US-NIH and NIAID in more details. pared a one The discussion was very fruitful and -day tour to boosted the motivation to enhance Frederick the collaboration between the two area, one- institutions Dr Lane also empha- hour drive sized the need for the extension of from NIH the implementation agreement INDONESIAN DELEGATION VISIT main campus, to visit laboratory between US-NIH and Indonesia TO THE US-NIH facilities. The first place was the NIHRD. Before noon, the delegation The Indonesian delegation was led biorepository laboratory where Dr was impressed by how the US-NIH by Dr. dr. Irmansyah, SpKJ. Other Marcia Lara explained in details the Library of Medicine was designed members were Dr. drg. Tati Suryati requirements of the specimens to to protect all the manuscripts from as the head of scientific review be stored in this facility, the proce- threats and by their collections board, NIHRD; dr Muhammad Kar- dures when specimens are received, from all over the world. At the end yana, MKes as the chair of INA- stored in hundreds of freezers, liq- of the visit, the delegation visited RESPOND Steering Committee; and uid nitrogen tanks, and walk-in the HIV clinic, and had a very valua- dr Herman Kosasih from INA- freezers with different tempera- ble discussion with DIAIDS and RESPOND scientific division. The tures, and shipped. In the afternoon RePORT team regarding our TRI- REPORT objectives of the visit that was con- the delegation visited For Detrick, POD and Pro-Active studies. At the ducted from 11-13 July 2018 were the US Army Campus where both end of the trip, Sophia prepare a to obtain information about the NIAID HIV laboratory and Integrat- dinner party to welcome and intro- NIH structure and its clinical re- ed Research Facilities (IRF) are lo- duce the delegation to all the team search facilities, funding and train- cated. In the HIV lab, Robin and Division of Clinical Research (DCR). ing available, and to discuss re- Helena shared their experience Thank you very much to all the DCR search opportunities. regarding HIV assays in their lab, team for your hospitality during our On the first day, Dr Chuen-Yen Lau and offered to assist INA-RESPOND stay. introduced all the integrative facili- reference lab to achieve ties of the clinical center, followed the same standard. At by a meeting with the National the end of the day, the Center for Complementary and delegation visited IRF, Integrative Health (NCCIH) to dis- which is part of the cuss current research conducted by National Interagency NIHRD and NCCIH and the possibil- Biodefense Campus, a ity of future collaboration. Later in group of federal bio- the afternoon, the delegation had a medical research facili- chance to attend how protocols, ties. Here the delega- including the schistosomiasis study, tion was escorted by were reviewed by NIAID scientific Michael Holbrook, the reviewed board. In late afternoon, chief of containment Dr Irmansyah had the opportunity supervisor, and were to discussed and shared ideas with fascinated by the ad- vanced imaging tech- nology and other state- 8 Issue #58 NewsletterINA-RESPOND Requesting Study Data for Publication By: M. HELMI AZIZ, M. MILA ERASTUTI, and NURHAYATI ince INA-RESPOND and inform you how to obtain team or network are welcome was established, the our study data for publication.
Load more

Recommended publications
  • A New Antibiotic Kills Pathogens Without Detectable Resistance
    ARTICLE doi:10.1038/nature14098 A new antibiotic kills pathogens without detectable resistance Losee L. Ling1*, Tanja Schneider2,3*, Aaron J. Peoples1, Amy L. Spoering1, Ina Engels2,3, Brian P. Conlon4, Anna Mueller2,3, Till F. Scha¨berle3,5, Dallas E. Hughes1, Slava Epstein6, Michael Jones7, Linos Lazarides7, Victoria A. Steadman7, Douglas R. Cohen1, Cintia R. Felix1, K. Ashley Fetterman1, William P. Millett1, Anthony G. Nitti1, Ashley M. Zullo1, Chao Chen4 & Kim Lewis4 Antibiotic resistance is spreading faster than the introduction of new compounds into clinical practice, causing a public health crisis. Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s. Synthetic approaches to produce antibiotics have been unable to replace this platform. Uncultured bacteria make up approximately 99% of all species in external environments, and are an untapped source of new antibiotics. We developed several methods to grow uncultured organisms by cultivation in situ or by using specific growth factors. Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured bacteria. Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid). We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin. The properties of this compound suggest a path towards developing antibiotics that are likely to avoid development of resistance. Widespread introduction of antibiotics in the 1940s, beginning with factors through the chambers enables growth of uncultured bacteria in penicillin1,2 and streptomycin3, transformed medicine, providing effec- their natural environment.
    [Show full text]
  • Bacteriocins, Potent Antimicrobial Peptides and the Fight Against Multi Drug Resistant Species: Resistance Is Futile?
    antibiotics Review Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile? Elaine Meade 1, Mark Anthony Slattery 2 and Mary Garvey 1,2,* 1 Department of Life Science, Sligo Institute of Technology, F91 YW50 Sligo, Ireland; [email protected] 2 Mark Anthony Slattery MVB, Veterinary Practice, Manorhamilton, F91 DP62 Leitrim, Ireland; [email protected] * Correspondence: [email protected]; Tel.: +353-071-9305529 Received: 31 December 2019; Accepted: 13 January 2020; Published: 16 January 2020 Abstract: Despite highly specialized international interventions and policies in place today, the rapid emergence and dissemination of resistant bacterial species continue to occur globally, threatening the longevity of antibiotics in the medical sector. In particular, problematic nosocomial infections caused by multidrug resistant Gram-negative pathogens present as a major burden to both patients and healthcare systems, with annual mortality rates incrementally rising. Bacteriocins, peptidic toxins produced by bacteria, offer promising potential as substitutes or conjugates to current therapeutic compounds. These non-toxic peptides exhibit significant potency against certain bacteria (including multidrug-resistant species), while producer strains remain insusceptible to the bactericidal peptides. The selectivity and safety profile of bacteriocins have been highlighted as superior advantages over traditional antibiotics; however, many aspects regarding their efficacy are still
    [Show full text]
  • Teixobactin - a Game Changer Antibiotic
    ERA’S JOURNAL OF MEDICAL RESEARCH VOL.7 NO.2 Review Article DOI:10.24041/ejmr2020.37 TEIXOBACTIN - A GAME CHANGER ANTIBIOTIC Sahil Hussain, Neelam Yadav Department of Pharmacy Era's Lucknow Medical College & Hospital, Era University Sarfarazganj Lucknow, U.P., India-226003 Received on : 28-09-2020 Accepted on : 26-12-2020 ABSTRACT Address for correspondence A team of scientist under the supervision of Kim Lewis from Northeastern University has discovered a novel antibiotic called Teixobactin, which Dr. Neelam Yadav kills the bacteria by inhibiting them from building their outer protein Department of Pharmacy envelop. The bacterial resistance interference are key challenges to the Era’s Lucknow Medical College & global health. Teixobactin shows exceptional antibacterial activities Hospital, Era University Lucknow-226003 against the range of pathogenic bacteria viz S. Aureus and Mycobacterium Email: [email protected] Tuberculosis. It is bactericidal and has many mode of operation, however Contact no: +91- it is one of the most important contribution in the modernization of medicine. However, the increase in Antibiotic resistance is at alarming rate and the ability of patient care through antibiotics is a challenge nowadays increment in Antibiotics resistance is among the top public health threats in the century 21". According to the Centers for Disease Control and Prevention (CDCP), around 23 thousand peoples die in every year in United States of America (USA) due to Antibiotic resistance. Whenever the patient is administered with an antibiotic the condition of the patient does not improve due to which more than 2 million people are sickened. The increase in Antibiotic resistance is much greater than the increase in epidemic diseases such as Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome (Al DS) or Ebola Virus Disease.
    [Show full text]
  • Raman Spectroscopic Studies of Inhibitor Reactions in Class A, B and D Β
    RAMAN SPECTROSCOPIC STUDIES OF INHIBITOR REACTIONS IN CLASS A, B AND D β-LACTAMASES by TAO CHE Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Adviser: Dr. Paul R. Carey Department of Biochemistry CASE WESTERN RESERVE UNIVERSITY May, 2015 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Tao Che candidate for the Ph.D. degree*. (signed) Focco van den Akker (chair of the committee) Paul Carey Robert Bonomo Menachem Shoham Marion Skalweit (date) December, 2014 *We also certify that written approval has been obtained for any proprietary material contained therein. i TABLE OF CONTENTS LIST OF TABLES ........................................................................................................... V LIST OF SCHEMES ...................................................................................................... VI LIST OF ABBREVIATIONS ....................................................................................... XV ABSTRACT .................................................................................................................. XVI CHAPTER I: INTRODUCTION .................................................................................... 1 I-1 Bacterial resistance to β-lactam antibiotics .............................................................. 5 I-2 β-Lactamases ............................................................................................................... 9 I-3 Raman techniques
    [Show full text]
  • Copyright by Natalie Kay Boyd 2020 the Dissertation Committee for Natalie Kay Boyd Certifies That This Is the Approved Version of the Following Dissertation
    Copyright by Natalie Kay Boyd 2020 The Dissertation Committee for Natalie Kay Boyd Certifies that this is the approved version of the following dissertation: THE IN VITRO ANTIBIOTIC ACTIVITY OF NON-ANTIBIOTIC DRUGS AGAINST S. AUREUS CLINICAL STRAINS Committee: Christopher R. Frei, Supervisor Kelly R. Reveles Jim M. Koeller Jose L. Lopez-Ribot Manjunath P. Pai THE IN VITRO ANTIBIOTIC ACTIVITY OF NON-ANTIBIOTIC DRUGS AGAINST S. AUREUS CLINICAL STRAINS by Natalie Kay Boyd Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin August 2020 Dedication I dedicated this dissertation to my family, friends, and colleagues, who have supported and loved me unconditionally. Abstract THE IN VITRO ANTIBIOTIC ACTIVITY OF NON-ANTIBIOTIC DRUGS AGAINST S. AUREUS CLINICAL STRAINS Natalie Kay Boyd, Ph.D. The University of Texas at Austin, 2020 Supervisor: Christopher R. Frei Drug repurposing, or identifying new uses for existing drugs, has emerged as an alternative to traditional drug discovery processes involving de novo synthesis. Drugs that are currently approved or under development for non- antibiotic indications may possess antibiotic properties, and therefore may have repurposing potential, either alone or in combination with an antibiotic. They might also serve as “antibiotic adjuvants” to enhance the activity of certain antibiotics. The objective of the proposed research is to utilize novel screening tools to characterize antibiotic effects of select non-antibiotic drugs against Staphylococcus aureus clinical isolates. We hypothesized that one or more of the non-antibiotic candidates selected for this study would demonstrate antibiotic activity against Staphylococcus aureus, either directly (as monotherapy) or indirectly (in combination with antibiotic drugs).
    [Show full text]
  • Synthesis and Structure−Activity Relationships of Teixobactin
    Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Special Issue: Antimicrobial Therapeutics Reviews REVIEW Synthesis and structure−activity relationships of teixobactin John A. Karas,1 Fan Chen,1 Elena K. Schneider-Futschik,1,2 Zhisen Kang,1 Maytham Hussein,1 James Swarbrick,1 Daniel Hoyer,1,3,4 Andrew M. Giltrap,5 Richard J. Payne,5 Jian Li,6 and Tony Velkov1 1Department of Pharmacology & Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, the University of Melbourne, Parkville, Victoria, Australia. 2Lung Health Research Centre, Department of Pharmacology & Therapeutics, the University of Melbourne, Parkville, Victoria, Australia. 3The Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Parkville, Victoria, Australia. 4Department of Molecular Medicine, the Scripps Research Institute, La Jolla, California. 5School of Chemistry, the University of Sydney, Sydney, New South Wales, Australia. 6Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia Address for correspondence: Tony Velkov and John A. Karas, Department of Pharmacology & Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, the University of Melbourne, Parkville, VIC 3010, Australia. [email protected] OR [email protected] The discovery of antibiotics has led to the effective treatment of bacterial infections that were otherwise fatal and has had a transformative effect on modern medicine. Teixobactin is an unusual depsipeptide natural product that was recently discovered from a previously unculturable soil bacterium and found to possess potent antibacterial activity against several Gram positive pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin- resistant Enterococci.
    [Show full text]
  • Methicillin-Resistant Staphylococcus Aureus in Diabetic Foot Infection In
    IJLXXX10.1177/1534734619853668The International Journal of Lower Extremity WoundsViswanathan et al 853668research-article2019 Original Review The International Journal of Lower Extremity Wounds Methicillin-Resistant Staphylococcus 1 –11 © The Author(s) 2019 Article reuse guidelines: aureus in Diabetic Foot Infection in sagepub.com/journals-permissions DOI:https://doi.org/10.1177/1534734619853668 10.1177/1534734619853668 India: A Growing Menace journals.sagepub.com/home/ijl Vijay Viswanathan, MD, PhD, FRCP1, Sharad Pendsey, MD2, Chandni Radhakrishnan, MD, PhD, FRCP3, Tushar Devidas Rege, MS4, Jaishid Ahdal, MD5 , and Rishi Jain, MD5 Abstract Diabetic foot infection (DFI) is a serious and common complication of diabetes mellitus. These infections are potentially disastrous and rapidly progress to deeper spaces and tissues. If not treated promptly and appropriately, DFI can be incurable or even lead to septic gangrene, which may require foot amputation. Mostly, these infections are polymicrobial, where Gram-positive pathogens mainly Staphylococcus aureus play a dominant causative role. Methicillin-resistant Staphylococcus aureus (MRSA) is present in 10% to 32% of diabetic infections and is associated with a higher rate of treatment failure, morbidity, and hospitalization cost in patients with DFIs. The increasing resistance of bacteria and the adverse effects pertaining to the safety and tolerability towards currently available anti-MRSA agents have limited the available treatment options for patients with DFI. Infection control, antimicrobial stewardship, and rapid diagnostics based on the microbiological culture and the antimicrobial susceptibility testing results are important components in helping curb this disturbing trend. Emphasis to revisit a vigorous research effort in order to improve the therapeutic options for the increasingly resistant and highly adaptable MRSA is the need of hour.
    [Show full text]
  • Teixobactin: a Powerful Tool for Combating Resistant Strains
    Review Article Teixobactin: A Powerful Tool for Combating Resistant Strains TEJAL RAWAL* AND SHITAL BUTANI Department of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad-382 481, India Rawal and Butani: Teixobactin against Drug-resistant Pathogens Resistance to antibiotics has grown out to be a serious health concern. Despite this serious health crisis, no new antibiotics have been discovered since the last 30 years. A new ray of hope in the form of teixobactin has come out of the dark, which could demonstrate the potential to be effective in countering resistance. This new antibiotic has an interesting mechanism of action against bacteria. The discovery of this wonderful compound has evolved as a major breakthrough especially in this era of antibiotic catastrophe. This review article highlights various facets of teixobactin that include chemistry, mode of action, in vitro and in vivo activities. Though the compound has not yet undergone clinical studies, its effect on mice models has given hope for overpowering resistance. This review attempts to provide information about teixobactin and its potential for fighting as antibiotic resistance. Key words: Teixobactin, antibiotic, Eleftheria terrae, iChip, resistance, antimicrobial A new crisis the world facing today is antibiotic which gained the title of 'remarkable drug' as well as resistance. Genetic modifications in bacteria have referred to as "magic bullet" by Paul Ehlrich, gained led to a condition, where pathogenic microorganisms these recognitions since it was highly effective have become more virulent and resistant to the against bacteria, without causing any harm to the available antimicrobial agents. The risk of resistance body. It was found to be effective against organisms, has also been accelerated due to overuse of the where sulphonamides failed.
    [Show full text]
  • Antimicrobial Drugs 601
    Chapter 14 | Antimicrobial Drugs 601 Chapter 14 Antimicrobial Drugs Figure 14.1 First mass produced in the 1940s, penicillin was instrumental in saving millions of lives during World War II and was considered a wonder drug.[1] Today, overprescription of antibiotics (especially for childhood illnesses) has contributed to the evolution of drug-resistant pathogens. (credit left: modification of work by Chemical Heritage Foundation; credit right: modification of work by U.S. Department of Defense) Chapter Outline 14.1 History of Chemotherapy and Antimicrobial Discovery 14.2 Fundamentals of Antimicrobial Chemotherapy 14.3 Mechanisms of Antibacterial Drugs 14.4 Mechanisms of Other Antimicrobial Drugs 14.5 Drug Resistance 14.6 Testing the Effectiveness of Antimicrobials 14.7 Current Strategies for Antimicrobial Discovery Introduction In nature, some microbes produce substances that inhibit or kill other microbes that might otherwise compete for the same resources. Humans have successfully exploited these abilities, using microbes to mass-produce substances that can be used as antimicrobial drugs. Since their discovery, antimicrobial drugs have saved countless lives, and they remain an essential tool for treating and controlling infectious disease. But their widespread and often unnecessary use has had an unintended side effect: the rise of multidrug-resistant microbial strains. In this chapter, we will discuss how antimicrobial drugs work, why microbes develop resistance, and what health professionals can do to encourage responsible use of antimicrobials.
    [Show full text]
  • New Antibiotics Against Bacterial Resistance
    REVISIÓN New antibiotics against bacterial resistance Lorena Liseth Cárdenas1, Maritza Angarita Merchán1, Diana Paola López1,* Abstract The evolution of bacterial resistance is generating a serious public health problem due to the indiscriminate use of antibiotics, the application of non-optimal doses, the irregularity in the taking of medicines sent by the health professional, factors that have affected the increase in the rate of antimicrobial resistance; It is important to generate strategies that contribute to diminishing it, including the rational use of antibiotics and the constant research of new therapeutic alterna- tives such as teixobactin, which is a product of the Gram negative bacterium called Eleftheria terrae, related to the genus Aquabacterium, is a microorganism that presents extremophile conditions, for which, a multichannel system of semipermeable membranes called Ichip was developed for its isolation. Eravacycline is a new fully synthetic bacteriostatic antibiotic of the tetracycline family, is a potent inhibitor based on the mechanism of the bacterial ribosome and exerts potent activity against a broad spectrum of susceptible and multiresistant bacteria. Keywords: teixobactin, eravacycline, tetracycline, bacterial resistance, lipid II, Eleftheria Terrae, Ichip. Nuevos antibióticos contra la resistencia bacteriana Resumen La evolución de la resistencia bacteriana ha generado un serio problema de salud pública debido al uso indiscriminado antibioticos, la aplicación de dosis no óptimas, la irregularidad en la toma de medicinas prescritas por el profesional de la salud han llevado a un aumento en la tasa de resistencia antimicrobiana; por ello es importante generar estrategias que contribuyan a disminuirla incluyendo el uso racional de anitibioticos y la búsqueda constante de nuevos antibioticos.
    [Show full text]
  • Teixobactin Provides Protection Against Inhalation Anthrax in the Rabbit Model
    pathogens Article Teixobactin Provides Protection against Inhalation Anthrax in the Rabbit Model William S. Lawrence 1,2,*, Jennifer E. Peel 1 , Satheesh K. Sivasubramani 3, Wallace B. Baze 4, Elbert B. Whorton 2, David W. C. Beasley 1,5, Jason E. Comer 1,5, Dallas E. Hughes 6, Losee L. Ling 6 and Johnny W. Peterson 1,2 1 Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA; [email protected] (J.E.P.); [email protected] (D.W.C.B.); [email protected] (J.E.C.); [email protected] (J.W.P.) 2 Institute for Human Infections & Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA; [email protected] 3 Directorate of Environmental Health Effects Laboratory, Naval Medical Research Unit, Dayton, OH 45433, USA; [email protected] 4 Department of Comparative Medicine, University of Texas MD Anderson Cancer Center, Bastrop, TX 78602, USA; [email protected] 5 Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX 77555, USA 6 NovoBiotic Pharmaceuticals, LLC, Cambridge, MA 02138, USA; [email protected] (D.E.H.); [email protected] (L.L.L.) * Correspondence: [email protected]; Tel.: +1-409-266-6919 Received: 21 August 2020; Accepted: 18 September 2020; Published: 22 September 2020 Abstract: The use of antibiotics is a vital means of treating infections caused by the bacteria Bacillus (B.) anthracis. Importantly, with the potential future use of multidrug-resistant strains of B. anthracis as bioweapons, new antibiotics are needed as alternative therapeutics. In this blinded study, we assessed the protective efficacy of teixobactin, a recently discovered antibiotic, against inhalation anthrax infection in the adult rabbit model.
    [Show full text]
  • Synergistic Antibacterial Activity of Silver with Antibiotics Correlating
    www.nature.com/scientificreports OPEN Synergistic antibacterial activity of silver with antibiotics correlating with the upregulation of the ROS Received: 14 December 2017 Accepted: 20 June 2018 production Published: xx xx xxxx Lili Zou1,2, Jun Wang2, Yu Gao3, Xiaoyuan Ren1, Martin E. Rottenberg3, Jun Lu1,4 & Arne Holmgren 1 Thiol-dependent enzymes, including the thioredoxin (Trx) and glutathione (GSH) systems, have recently been found as promising bactericidal targets in multidrug-resistant (MDR) bacteria. We previously discovered that silver acted synergistically with ebselen in the inhibition of the Trx system and also resulted in a fast depletion of GSH in Gram-negative bacteria. Silver has been found by others to improve the sensitivity of bacteria to certain conventional antibiotics. Here, we found that the synergistic antibacterial efects of silver with four conventional antibiotics was correlated with the blockage of bacterial Trx system by silver. The synergistic antibacterial efect came along with the production of reactive oxygen species. All these results suggested that silver primarily enhanced the bactericidal activities of conventional antibiotics towards Gram-negative strains through the upregulation of ROS production. Te worldwide ever-increasing of bacterial resistance to the conventional medical antimicrobial agents is cur- rently one of the most serious health crisis for modern medicine1–5. Tis has serious negative impacts such as decreases of the effectiveness of existing treatments, and causes higher morbidity and mortality rates in patients with infections caused by multidrug-resistant (MDR) bacteria1,2,6. European Antimicrobial Resistance Surveillance Network (EARS-Net) latest data showed high and increasing resistance of Gram-negative bacteria, which are combined with resistance to third-generation cephalosporins, fuoroquinolones, and aminoglycosides for both Escherichia coli and Klebsiella pneumoniae7.
    [Show full text]